altamiratherapeutics.com (CYTO) - Long-Term Debt to Capital Coefficient

This daily price chart for Altamira Therapeutics (CYTO) reflects the asset's dynamics, where the indicator stands at 0.00. The business focuses on inner ear treatments while facing threats of funding shortages and past test failures. Patents for RNA transport nanoparticles serve as a defense, creating a high barrier to entry. The sector relies on an autonomous innovation cycle, remaining resilient to global crises.

Long-term debt-to-equity measures the proportion of liabilities with a maturity of more than one year relative to shareholders' equity. For Altamira Therapeutics (CYTO), this balance is critical, as the development of RNA-based drugs requires stable funding regardless of market cycles. Analyzing the long-term debt-to-equity ratio allows for an assessment of default risk during the prolonged creation of a pipeline. Low leverage confirms the financial stability of the business. Such assets are characterized by a high degree of protection against macroeconomic volatility.